- ISIN
- US5787841007
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 31, 2025
Highlights
- Market Cap
- $1.49B
- Enterprise Value
- $1.32B
- EPS (TTM)
- -$2.58
- Gross Profit (TTM)
- -$1.15M
- EBITDA (TTM)
- -$126.66M
- Year Range
- $12.81 - $53.65
- Target Price
- $59.43
- ROA (TTM)
- -29.20%
- ROE (TTM)
- -35.86%
- Avg. Volume (1M)
- 470K
- Avg. Volume Value (1M)
- $14.01M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MAZE Performance Chart
Maze Therapeutics, Inc (MAZE) is down 35.0% since the beginning of the year. At $27 per share, MAZE is trading 49.8% below its 52-week high of $54.
Loading charts...
Compare this symbol against anything
Returns By Period
Maze Therapeutics, Inc (MAZE) has returned -35.02% so far this year and 80.67% over the past 12 months.
Maze Therapeutics, Inc
- 1D
- -2.57%
- 1M
- -13.88%
- 6M
- -38.23%
- YTD
- -35.02%
- 1Y
- 80.67%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 40.92%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
MAZE Monthly Returns History
Based on dividend-adjusted daily data since Jan 31, 2025, MAZE's average daily return is +0.30%, while the average monthly return is +5.06%. At this rate, an investment would double in approximately 1.2 years.
Historically, 53% of months were positive and 47% were negative. The best month was Sep 2025 with a return of +79.0%, while the worst month was Mar 2026 at -34.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.
On a daily basis, MAZE closed higher 51% of trading days. The best single day was Sep 11, 2025 with a return of +54.8%, while the worst single day was Mar 25, 2026 at -35.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.19% | 4.61% | -34.53% | -10.95% | -0.45% | 12.77% | -9.79% | -35.02% | |||||
| 2025 | -1.05% | -23.32% | -9.98% | -15.99% | 8.22% | 22.58% | 20.21% | -1.76% | 78.95% | 26.92% | 14.71% | 9.75% | 157.01% |
Benchmark Metrics
Maze Therapeutics, Inc has an annualized alpha of 82.99%, beta of 0.90, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since January 31, 2025.
- This stock captured 711.00% of S&P 500 Index gains and 347.28% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 82.99%
- Beta
- 0.90
- R²
- 0.03
- Upside Capture
- 711.00%
- Downside Capture
- 347.28%
Return for Risk
Risk / Return Rank
MAZE ranks 76 for risk / return — above 76% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Maze Therapeutics, Inc (MAZE) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MAZE | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.42 | ||
| Sortino ratioReturn per unit of downside risk | -0.04 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.25 | +0.03 |
| Calmar ratioReturn relative to maximum drawdown | 1.52 | 2.00 | -0.48 |
| Martin ratioReturn relative to average drawdown | 2.89 | 8.49 | -5.61 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Maze Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Maze Therapeutics, Inc was 54.51%, occurring on Jun 8, 2026. The portfolio has not yet recovered.
The current Maze Therapeutics, Inc drawdown is 48.07%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-54.51%Jun 2026 | 2mo 27d | — | 4mo 22dMar 2026 - now | — |
-53.04%Apr 2025 | 2mo 7d | 3mo 9d | 5mo 16dJan 2025 - Jul 2025 | 2025 selloff2025 |
-26.10%Aug 2025 | 18d | 1mo 4d | 1mo 22dJul 2025 - Sep 2025 | — |
-13.96%Nov 2025 | 3d | 10d | 13dNov 2025 - Nov 2025 | — |
-9.93%Jan 2026 | 1mo 2d | 14d | 1mo 16dDec 2025 - Jan 2026 | — |
Drawdown Indicators
| MAZE | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -54.51% | -56.78% | +2.27% |
Max Drawdown (1Y)Largest decline over 1 year | -54.51% | -9.10% | -45.41% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -48.07% | -1.58% | -46.49% |
Average DrawdownAverage peak-to-trough decline | -23.12% | -10.70% | -12.42% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 28.69% | 2.14% | +26.55% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Maze Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Maze Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MAZE in comparison with other companies in the Biotechnology industry. Currently, MAZE has a P/B value of 4.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MAZE
Add Maze Therapeutics, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MAZE